Autoantibodies to the Atheroma Component Beta2-Glycoprotein I and Risk of Symptomatic Peripheral Artery Disease

Abstract

Peripheral artery disease (PAD) is mostly related to atherosclerosis. Autoimmunity and, in particular, antibodies to cardiolipin (aCL) and phospholipid cofactors such as beta2-glycoprotein I (beta2-gpI) might influence the development of atheroma. Beta2-glycoprotein I (beta2-gpI) has been found in atheroma. It has previously been shown that immunoglobulin A (IgA) anti-beta2-gpI antibodies are associated with a risk of cerebral ischemia and myocardial infarction. This case control study aimed to determine whether elevated levels of aCL/anti-beta2-gpI antibodies are associated with a risk of symptomatic PAD (sPAD). Cases comprised a nonselected population of patients with sPAD (intermittent claudication or critical ischemia). Patient recruitment was based on arteriography changes. Controls were selected from patients admitted to orthopedic wards as a result of fractures or muscle-ligamentous disorders. Age, sex, race, hypertension, smoking, diabetes mellitus, and hypercholesterolemia were evaluated as risk factors in both groups. IgG/IgM/IgA aCL and anti-beta2-gpI were detected by enzyme-linked immunoabsorbant assays (ELISA). To estimate the grade of association of antibodies with sPAD, odds ratios (OR) were calculated. Logistic regression was utilized for adjustment of confounding factors. Seventy-seven cases and 93 controls were studied. The mean age was 61.5 years for cases and 47.5 years for controls (p <0.001). Among the risk factors evaluated, the presence of hypertension showed the strongest association with sPAD (OR 12.1; 95%CI 5.8—30). The presence of IgA anti-beta2-gpI was independently associated with sPAD (OR 5.4; 95%CI 1.8—15.8; p = 0.01). IgA aCL was strongly associated with the outcome (nonadjusted OR 11.5 after Agresti correction). IgA aCL and IgA anti-beta2-gpI antibodies were not associated with any known risk factors for sPAD or with arteriography changes. The occurrence of these autoantibodies might represent one of the links between autoimmunity and atherosclerosis in patients with sPAD.

Get full access to this article

View all access options for this article.

References

Wick G. , Xu Q. : Atherosclerosis: An autoimmune disease . Exp Gerontol 34: 559-566 , 1999.

George J. , Harats D. , Gilburd B. , et al: Immunolocalization of beta2-gpI (apolipoprotein H) to human atherosclerotic plaques: Potential implications for lesion progression . Circulation 99: 2227-2230 , 1999.

Wilson WA , Gharavi AE , Koike T. , et al: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome . Arthritis Rheum 42: 1309-1311 , 1999.

Cervera R. , Piette JC , Font J. , et al: Antiphospholipid syndrome. Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients . Arthritis Rheum 46: 1019-1027 , 2002.

Kandiah DA , Krilis S. : Beta2-gpI . Lupus 3: 207-212 , 1994.

Gharavi AE , Sammaritano LR , Wen J. , et al: Induction of antiphospholipid antibodies by immunization with beta2-gpI (apolipoprotein H) . J Clin Invest 90: 1105-1109 , 1992.

Cabiedes J. , Cabral A. , Alarcon-Segovia D. : Clinical manifestation of antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta2-gpI than with antiphospholipid antibodies . J Rheumatol 22: 1899-1906 , 1995.

Staub HL , Norman GL , Crowther T. , et al: Autoantibodies to atherosclerotic plaque components beta2-glycoprotein I and heat-shock proteins as risk factors for acute cerebral ischemia . Arq Neuropsiquiatr 61: 757-763 , 2003.

Ranzolin A. , Bohn JM , Norman GL , et al: Anti-beta2-glycoprotein I antibodies as risk factors for acute myocardial infarction . Arq Bras Cardiol 83: 137-140 , 2004.

10.

Weitz JI , Byrne J. , Clagett P. , et al: Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: A critical review . Circulation 94: 3026-3049 , 1996.

11.

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report . JAMA 289: 2560-2572 , 2003 .

12.

Donahue RP , Abbott RD , Reed DM , et al: Physical activity and coronary heart disease in middle-aged and elderly men . The Honolulu Heart Program. Am J Public Health 78: 683-685 , 1988.

13.

Gharavi AE , Harris EN , Asherson RA , et al: Antiphospholipid antibodies: Isotype distribution and phospholipid specificity . Ann Rheum Dis 46: 1-6 , 1987.

14.

Lewis S. , Keil LB , Binder WL , et al: Standardized measurement of major immunoglobulin class (IgG, IgA, IgM) antibodies to beta2-gpI in patients with antiphospholipid syndrome . J Clin Lab Analysis 12: 293-297 , 1998.

15.

Hopkins WG : A new view of statistics. On line. http://www.sportsci.org/resource/stats/index . Captured April 11, 2002.

16.

Agresti A. : Categorical Data Analysis. New York: Wiley , 1990.

17.

Diez Bjm , Garcia Dvjl , Pelegrina TJ , et al: Cardiovascular disease epidemiology and risk factors in primary care . Rev Esp Cardiol 58: 367-373 , 2005.

18.

Wattanakit K. , Folsom AR , Selvin E. , et al: Risk factors for peripheral arterial disease incidence in persons with diabetes: The atherosclerosis risk in communities (ARIC) study . Atherosclerosis 180: 389-397 , 2005.

19.

Wilson WA , Faghiri Z. , Taheri F. , et al: Significance of IgA antiphospholipid antibodies . Lupus 7(suppl 2): S110-113 , 1998 .

20.

Metz LM , Edworthy S. , Mydlarski R. , et al: The frequency of phospholipid antibodies in an unselected stroke population . Can J Neurol Sci 25: 64-69 , 1998.

21.

Lam EY , Taylor LM Jr , Landry GJ , et al: Relationship between antiphospholipid antibodies and progression of lower extremity arterial occlusive disease after lower extremity bypass operations . J Vasc Surg 33: 976-982 , 2001.

22.

de Godoy JMP , Batigália F. , de Godoy MRP , et al: Anticardiolipin antibodies as a risk factor for atherosclerosis in intermittent claudication . Angiology 55: 357-359 , 2004.

23.

Evans SM , Brittenden J. , Adam DJ , et al: Vascular Surgical Society of Great Britain and Ireland: Prevalence and significance of thrombophilia in patients with intermittent claudication . Br J Surg 86: 702-703 , 1999.

24.

Puisieux F. , de Groote P. , Masy E. , et al: Association between anticardiolipin antibodies and mortality in patients with peripheral arterial disease . Am J Med 109: 635-641 , 2000.

25.

Friehs I. , Eber B. , Friehs G. , et al: IgG anticardiolipin antibodies are markers for cerebral and peripheral artery disease . Vasa 21: 158-162 , 1992.

26.

George J. , Afek A. , Gilburd B. : Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-gpI . Circulation 98: 1108-1115 , 1998.

27.

Harats D. , George J. : Beta-2-glycoprotein I and atherosclerosis . Curr Opin Lipidol 12: 543-546 , 2001.

28.

Veres K. , Lakos G. , Kerenyi A. , et al: Antiphospholipid antibodies in acute coronary syndrome . Lupus 13: 423-427 , 2004.

29.

Lopez LR , Dier KJ , Lopez D. , et al: Anti-beta2-glycoprotein i and antiphosphatidylserine antibodies are predictor of arterial thrombosis in patients with antiphospholipid syndrome . Am J Clin Pathol 121: 142-149 , 2004.

30.

Matsuura E. , Kobayashi K. , Koike T. , et al: Auto-antibody-mediated atherosclerosis . Autoimmun Rev 1: 348-353 , 2002.

31.

Medeiros AM , von Mühlen CA , Ketelhuth DF , et al: Antibody against oxidized low-density lipoprotein increases in acute coronary syndromes [abstract 1721 in CD-ROM] . In: European Society of Cardiology Congress, 2004, Aug 28—Sept 1, Munich, Germany.

32.

Hasunuma Y. , Matsuura E. , Makita Z. , et al: Involvement of beta 2-glycoprotein I and anticardiolipin . Clin Exp Immunol 107: 560-573 , 1997.

33.

Kobayashi K. , Kishi M. , Atsumi T. , et al: Circulating oxidized LDL forms complexes with beta2-glycoprotein I: Implication as an atherogenic autoantigen . J Lipid Research 44: 716-726 , 2003.

34.

Matsuura E. , Kobayashi K. , Shoenfeld Y. , et al: Atherogenic role of protein-modified oxidized low-density lipoprotein and their autoantibodies. In: From Animal Models to Human Genetics: Research on the Induction Pathogenicity of Autoantibodies, ed. 1, ed. by Conrad K , Bachmann MP , Chan EKL , et al. Rockledge, FL: Pabst Science Publishers , 2004, pp 388-405.

35.

Shen L. : Receptors for IgA on phagocytic cells . Immunol Res 11: 273-282 , 1992.

36.

van Egmond M. , Hanneke van Vuuren AJ , van de Winkel JG , et al: The human Fc receptor for IgA (Fc alpha RI, CD89) on transgenic peritoneal macrophages triggers phagocytosis and tumor cell lysis . Immunol Lett 68: 83-87 , 1999.